RXRX

Recursion Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-25

Figures on this page computed 2026-11-07 11:56 UTC

Last close

3.88USD

Market data, 2026-11-04

RXRX: weekly closes from 4.62 on 2025-11-07 to 3.88 on 2026-11-04, a move of -16.0%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: -16.0%

Except where said otherwise: 10-K for 2025, filed 2026-02-25

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-25
The filing itself
-133.9%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
The filing itself
-863.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
-506.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
0.09Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Margins is the furthest below its sector's middle: 0.06 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.23x

2.24x

1.79x

1.44x

0.41x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-25

Sales2.23x
Its own average over 7 years, 33.5M.
Profit2.24x
Its own average over 7 years, -287.3M.
Free cash flow1.79x
Its own average over 7 years, -211.7M.
Debt1.44x
Its own average over 5 years, 66.8M.
Price0.41x
Its own average over 6 years, 9. Market data, 2026-11-04

Profit is furthest from its own average, at 2.24 times.

The filed years, as a table

Each line is 100 at 2019-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2019-12-31	100.0	100.0
2020-12-31	170.8	101.0
2021-12-31	438.9	581.1
2022-12-31	1,718.1	813.8
2023-12-31	1,922.2	963.6
2024-12-31	2,537.3	1,271.2
2025-12-31	3,220.4	2,074.4

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001601830-26-000039
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001601830-26-000039
Reported in: USD

The filing itself

Figures behind the shape

Growth

79.9%

faster is higher, placed against 4,950 companies as of 2026-11-06

Five-year revenue growth rate79.9%
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
One-year change in net income-39.1%
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Returns on capital

-133.9%

higher is higher, placed against 5,089 companies as of 2026-11-06

Return on invested capital-133.9%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
The filing itself
Return on equity-57.0%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
The filing itself
Return on assets-43.7%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
The filing itself

Margins

5.0%

wider is higher, placed against 3,412 companies as of 2026-11-06

Gross margin5.0%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Operating margin-867.9%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Net margin-863.4%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Free cash flow margin-506.5%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself

Price

1.4x

cheaper is higher, placed against 4,362 companies as of 2026-11-06

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-25
The filing itself
Price to book1.4x10-Q for 2025, filed 2026-11-02
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001601830-26-000145
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-11-02
- computed
- 10-K for 2025, filed 2026-02-25
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
- 10-K for 2025, filed 2026-02-25
The filing itself
Price to sales ratio21.1x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself

Safety

0.09

safer is higher, placed against 3,227 companies as of 2026-11-06

Debt to equity0.09
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
The filing itself
Current ratio5.5010-Q for 2025, filed 2026-11-02
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001601830-26-000145
Reported in
USD
- 10-Q for 2025, filed 2026-11-02
- 10-Q for 2025, filed 2026-11-02
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Altman Z-Score-0.08
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-06
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001601830-26-000039
Reported in
USD
- 10-K for 2025, filed 2026-02-25
- Computed from the 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.